Peapod Lane Capital LLC purchased a new stake in Climb Bio, Inc. (NASDAQ:CLYM - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 553,816 shares of the company's stock, valued at approximately $676,000. Peapod Lane Capital LLC owned about 0.82% of Climb Bio at the end of the most recent quarter.
Separately, Bank of New York Mellon Corp purchased a new position in shares of Climb Bio in the 1st quarter worth approximately $79,000. Hedge funds and other institutional investors own 69.76% of the company's stock.
Climb Bio Price Performance
Shares of CLYM traded up $0.02 during mid-day trading on Friday, reaching $1.37. 245,280 shares of the company's stock traded hands, compared to its average volume of 382,300. The stock's 50-day moving average is $1.25 and its two-hundred day moving average is $1.43. Climb Bio, Inc. has a 12 month low of $1.05 and a 12 month high of $9.21. The stock has a market cap of $92.58 million, a P/E ratio of -0.58 and a beta of -0.13.
Climb Bio (NASDAQ:CLYM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.16). Research analysts predict that Climb Bio, Inc. will post -1.57 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. BTIG Research started coverage on Climb Bio in a report on Thursday, May 22nd. They set a "buy" rating on the stock. Oppenheimer started coverage on shares of Climb Bio in a research note on Friday, June 6th. They issued an "outperform" rating and a $10.00 target price on the stock.
Get Our Latest Stock Analysis on CLYM
Climb Bio Profile
(
Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Further Reading
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
